Advertisement

Journal of Cancer Research and Clinical Oncology

, Volume 145, Issue 10, pp 2413–2422 | Cite as

PLK4: a promising target for cancer therapy

  • Yi Zhao
  • Xin WangEmail author
Review – Cancer Research

Abstract

Purpose

Polo-like kinase 4 (PLK4) is a serine/threonine protein kinase that regulates centriole duplication. PLK4 deregulation causes centrosome number abnormalities, mitotic defects, chromosomal instability and, consequently, tumorigenesis. Therefore, PLK4 has emerged as a therapeutic target for the treatment of multiple cancers. In this review, we summarize the critical role of centrosome amplification and PLK4 in cancer. We also highlight recent advances in the development of PLK4 inhibitors and discuss potential combination therapies for cancer.

Methods

The relevant literature from PubMed is reviewed in this article. The ClinicalTrials.gov database was searched for clinical trials related to the specific topic.

Results

PLK4 is aberrantly expressed in multiple cancers and has prognostic value. Targeting PLK4 with inhibitors suppresses tumor growth in vitro and in vivo.

Conclusions

PLK4 plays an important role in centrosome amplification and tumor progression. PLK4 inhibitors used alone or in combination with other drugs have shown significant anticancer efficacy, suggesting a potential therapeutic strategy for cancer. The results of relevant clinical trials await evaluation.

Keywords

PLK4 Centrosomes PLK4 inhibitor CFI-400945 Cancer 

Notes

Funding

This study was funded by National Natural Science Foundation (No. 81270598, No. 81473486, and No. 81770210); Key Research and Development Program of Shandong Province (No. 2018CXGC1213); Technology Development Projects of Shandong Province (No. 2017GSF18189); Taishan Scholar Foundation of Shandong Province; Shandong Provincial Engineering Research Center of Lymphoma; Key Laboratory for Kidney Regeneration of Shandong Province.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflicts of interest.

Statement of human and animal rights

This article does not contain any studies with human participants or animals performed by any of the authors.

Informed consent

Human participants were not involved in the study.

References

  1. Anderhub SJ, Kramer A, Maier B (2012) Centrosome amplification in tumorigenesis. Cancer Lett 322:8–17.  https://doi.org/10.1016/j.canlet.2012.02.006 CrossRefGoogle Scholar
  2. Archambault V, Lepine G, Kachaner D (2015) Understanding the Polo Kinase machine. Oncogene 34:4799–4807.  https://doi.org/10.1038/onc.2014.451 CrossRefGoogle Scholar
  3. Bao J et al (2018) MiR-126 negatively regulates PLK-4 to impact the development of hepatocellular carcinoma via ATR/CHEK1 pathway. Cell Death Dis 9:1045.  https://doi.org/10.1038/s41419-018-1020-0 CrossRefGoogle Scholar
  4. Boveri T (2008) Concerning the origin of malignant tumours by Theodor Boveri. Translated and annotated by Henry Harris. J Cell Sci 121(Suppl 1):1–84.  https://doi.org/10.1242/jcs.025742 CrossRefGoogle Scholar
  5. Chan JY (2011) A clinical overview of centrosome amplification in human cancers. Intern J Biol Sci 7:1122–1144CrossRefGoogle Scholar
  6. Coelho PA et al (2015) Over-expression of Plk4 induces centrosome amplification, loss of primary cilia and associated tissue hyperplasia in the mouse. Open Biol 5:150209.  https://doi.org/10.1098/rsob.150209 CrossRefGoogle Scholar
  7. Cunha-Ferreira I et al (2009) The SCF/Slimb ubiquitin ligase limits centrosome amplification through degradation of SAK/PLK4. Curr Biol 19:43–49.  https://doi.org/10.1016/j.cub.2008.11.037 CrossRefGoogle Scholar
  8. Denu RA, Zasadil LM, Kanugh C, Laffin J, Weaver BA, Burkard ME (2016) Centrosome amplification induces high grade features and is prognostic of worse outcomes in breast cancer. BMC Cancer 16:47.  https://doi.org/10.1186/s12885-016-2083-x CrossRefGoogle Scholar
  9. Denu RA, Shabbir M, Nihal M, Singh CK, Longley BJ, Burkard ME, Ahmad N (2018) Centriole Overduplication is the Predominant Mechanism Leading to Centrosome Amplification in Melanoma. Mol Cancer Res 16:517–527.  https://doi.org/10.1158/1541-7786.Mcr-17-0197 CrossRefGoogle Scholar
  10. Fischer M, Quaas M, Wintsche A, Muller GA, Engeland K (2014) Polo-like kinase 4 transcription is activated via CRE and NRF1 elements, repressed by DREAM through CDE/CHR sites and deregulated by HPV E7 protein. Nucleic Acids Res 42:163–180.  https://doi.org/10.1093/nar/gkt849 CrossRefGoogle Scholar
  11. Fischer M, Quaas M, Steiner L, Engeland K (2016) The p53-p21-DREAM-CDE/CHR pathway regulates G2/M cell cycle genes. Nucleic Acids Res 44:164–174.  https://doi.org/10.1093/nar/gkv927 CrossRefGoogle Scholar
  12. Fournier M et al (2016) KAT2A/KAT2B-targeted acetylome reveals a role for PLK4 acetylation in preventing centrosome amplification. Nat Commun 7:13227.  https://doi.org/10.1038/ncomms13227 CrossRefGoogle Scholar
  13. Gemble S, Basto R (2018) Fast and furious… or not, Plk4 dictates the pace. J Cell Biol 217:1169–1171.  https://doi.org/10.1083/jcb.201802084 CrossRefGoogle Scholar
  14. Godinho SA et al (2014) Oncogene-like induction of cellular invasion from centrosome amplification. Nature 510:167–171.  https://doi.org/10.1038/nature13277 CrossRefGoogle Scholar
  15. Gonczy P (2015) Centrosomes and cancer: revisiting a long-standing relationship. Nat Rev Cancer 15:639–652.  https://doi.org/10.1038/nrc3995 CrossRefGoogle Scholar
  16. Habedanck R, Stierhof YD, Wilkinson CJ, Nigg EA (2005) The Polo kinase Plk4 functions in centriole duplication. Nat Cell Biol 7:1140–1146.  https://doi.org/10.1038/ncb1320 CrossRefGoogle Scholar
  17. Helmke C, Becker S, Strebhardt K (2016) The role of Plk3 in oncogenesis. Oncogene 35:135–147.  https://doi.org/10.1038/onc.2015.105 CrossRefGoogle Scholar
  18. Holland AJ, Cleveland DW (2014) Polo-like kinase 4 inhibition: a strategy for cancer therapy? Cancer Cell 26:151–153.  https://doi.org/10.1016/j.ccr.2014.07.017 CrossRefGoogle Scholar
  19. Holland AJ, Lan W, Niessen S, Hoover H, Cleveland DW (2010) Polo-like kinase 4 kinase activity limits centrosome overduplication by autoregulating its own stability. J Cell Biol 188:191–198.  https://doi.org/10.1083/jcb.200911102 CrossRefGoogle Scholar
  20. Holland AJ et al (2012) Polo-like kinase 4 controls centriole duplication but does not directly regulate cytokinesis. Mol Biol Cell 23:1838–1845.  https://doi.org/10.1091/mbc.e11-12-1043 CrossRefGoogle Scholar
  21. Hudnall SD, Meng H, Lozovatsky L, Li P, Strout M, Kleinstein SH (2016) Recurrent genetic defects in classical Hodgkin lymphoma cell lines. Leuk Lymphoma 57:2890–2900.  https://doi.org/10.1080/10428194.2016.1177179 CrossRefGoogle Scholar
  22. Jana SC, Bazan JF, Bettencourt-Dias M (2012) Polo boxes come out of the crypt: a new view of PLK function and evolution. Structure 20:1801–1804.  https://doi.org/10.1016/j.str.2012.10.008 CrossRefGoogle Scholar
  23. Kawakami M et al (2018a) Polo-like kinase 4 inhibition produces polyploidy and apoptotic death of lung cancers. Proc Natl Acad Sci USA 115:1913–1918.  https://doi.org/10.1073/pnas.1719760115 CrossRefGoogle Scholar
  24. Kawakami M et al (2018b) Reply to Oegema et al. CFI-400945 and Polo-like kinase 4 inhibition. Proc Natl Acad Sci USA 115:E10810–e10811.  https://doi.org/10.1073/pnas.1813967115 CrossRefGoogle Scholar
  25. Kazazian K et al (2017) Plk4 promotes cancer invasion and metastasis through Arp2/3 complex regulation of the actin cytoskeleton. Cancer Res 77:434–447.  https://doi.org/10.1158/0008-5472.can-16-2060 CrossRefGoogle Scholar
  26. Klebba JE, Buster DW, McLamarrah TA, Rusan NM, Rogers GC (2015) Autoinhibition and relief mechanism for Polo-like kinase 4. Proc Natl Acad Sci USA 112:E657–E666.  https://doi.org/10.1073/pnas.1417967112 CrossRefGoogle Scholar
  27. Kleylein-Sohn J, Westendorf J, Le Clech M, Habedanck R, Stierhof YD, Nigg EA (2007) Plk4-induced centriole biogenesis in human cells. Dev Cell 13:190–202.  https://doi.org/10.1016/j.devcel.2007.07.002 CrossRefGoogle Scholar
  28. Ko MA, Rosario CO, Hudson JW, Kulkarni S, Pollett A, Dennis JW, Swallow CJ (2005) Plk4 haploinsufficiency causes mitotic infidelity and carcinogenesis. Nat Genet 37:883–888.  https://doi.org/10.1038/ng1605 CrossRefGoogle Scholar
  29. Kulukian A, Holland AJ, Vitre B, Naik S, Cleveland DW, Fuchs E (2015) Epidermal development, growth control, and homeostasis in the face of centrosome amplification. Proc Natl Acad Sci USA 112:E6311–E6320.  https://doi.org/10.1073/pnas.1518376112 CrossRefGoogle Scholar
  30. Ledoux AC, Sellier H, Gillies K, Iannetti A, James J, Perkins ND (2013) NFkappaB regulates expression of Polo-like kinase 4. Cell Cycle 12:3052–3062.  https://doi.org/10.4161/cc.26086 CrossRefGoogle Scholar
  31. Lei Q et al (2018) YLT-11, a novel PLK4 inhibitor, inhibits human breast cancer growth via inducing maladjusted centriole duplication and mitotic defect. Cell Death Dis 9:1066.  https://doi.org/10.1038/s41419-018-1071-2 CrossRefGoogle Scholar
  32. Levine MS et al (2017) Centrosome amplification is sufficient to promote spontaneous tumorigenesis in mammals. Dev Cell 40(313–322):e315.  https://doi.org/10.1016/j.devcel.2016.12.022 Google Scholar
  33. Li J, Tan M, Li L, Pamarthy D, Lawrence TS, Sun Y (2005) SAK, a new polo-like kinase, is transcriptionally repressed by p53 and induces apoptosis upon RNAi silencing. Neoplasia 7:312–323CrossRefGoogle Scholar
  34. Li Z, Dai K, Wang C, Song Y, Gu F, Liu F, Fu L (2016) Expression of polo-like kinase 4(PLK4) in breast cancer and its response to taxane-based neoadjuvant chemotherapy. J Cancer 7:1125–1132.  https://doi.org/10.7150/jca.14307 CrossRefGoogle Scholar
  35. Li S, Wang C, Wang W, Liu W, Zhang G (2018) Abnormally high expression of POLD1, MCM2, and PLK4 promotes relapse of acute lymphoblastic leukemia. Medicine (Baltimore) 97:e10734.  https://doi.org/10.1097/md.0000000000010734 CrossRefGoogle Scholar
  36. Liu L, Zhang CZ, Cai M, Fu J, Chen GG, Yun J (2012) Downregulation of polo-like kinase 4 in hepatocellular carcinoma associates with poor prognosis. PLoS One 7:e41293.  https://doi.org/10.1371/journal.pone.0041293 CrossRefGoogle Scholar
  37. Lohse I, Mason J, Cao PM, Pintilie M, Bray M, Hedley DW (2017) Activity of the novel polo-like kinase 4 inhibitor CFI-400945 in pancreatic cancer patient-derived xenografts. Oncotarget 8:3064–3071.  https://doi.org/10.18632/oncotarget.13619 CrossRefGoogle Scholar
  38. Lopes CAM et al (2018) Centrosome amplification arises before neoplasia and increases upon p53 loss in tumorigenesis. J Cell Biol.  https://doi.org/10.1083/jcb.201711191 Google Scholar
  39. Lowery DM, Lim D, Yaffe MB (2005) Structure and function of Polo-like kinases Oncogene 24:248–259.  https://doi.org/10.1038/sj.onc.1208280 Google Scholar
  40. Maniswami RR et al (2018) PLK4: a link between centriole biogenesis and cancer. Expert Opin Ther Targets 22:59–73.  https://doi.org/10.1080/14728222.2018.1410140 CrossRefGoogle Scholar
  41. Marina M, Saavedra HI (2014) Nek2 and Plk4: prognostic markers, drivers of breast tumorigenesis and drug resistance. Front Biosci (Landmark Ed) 19:352–365CrossRefGoogle Scholar
  42. Mason JM et al (2014) Functional characterization of CFI-400945, a Polo-like kinase 4 inhibitor, as a potential anticancer agent. Cancer Cell 26:163–176.  https://doi.org/10.1016/j.ccr.2014.05.006 CrossRefGoogle Scholar
  43. Mittal K, Ogden A, Reid MD, Rida PC, Varambally S, Aneja R (2015) Amplified centrosomes may underlie aggressive disease course in pancreatic ductal adenocarcinoma. Cell Cycle 14:2798–2809.  https://doi.org/10.1080/15384101.2015.1068478 CrossRefGoogle Scholar
  44. Morris EJ et al (2017) Stat3 regulates centrosome clustering in cancer cells via Stathmin/PLK1. Nat Commun 8:15289.  https://doi.org/10.1038/ncomms15289 CrossRefGoogle Scholar
  45. Nakamura T, Saito H, Takekawa M (2013) SAPK pathways and p53 cooperatively regulate PLK4 activity and centrosome integrity under stress. Nat Commun 4:1775.  https://doi.org/10.1038/ncomms2752 CrossRefGoogle Scholar
  46. Pellegrino R et al (2010) Oncogenic and tumor suppressive roles of polo-like kinases in human hepatocellular carcinoma. Hepatology 51:857–868.  https://doi.org/10.1002/hep.23467 Google Scholar
  47. Pihan GA, Wallace J, Zhou Y, Doxsey SJ (2003) Centrosome abnormalities and chromosome instability occur together in pre-invasive carcinomas. Cancer Res 63:1398–1404Google Scholar
  48. Press MF et al (2019) Role for polo-like kinase 4 in mediation of cytokinesis. Proc Natl Acad Sci 116:11309–11318.  https://doi.org/10.1073/pnas.1818820116 CrossRefGoogle Scholar
  49. Quaas M, Muller GA, Engeland K (2012) p53 can repress transcription of cell cycle genes through a p21(WAF1/CIP1)-dependent switch from MMB to DREAM protein complex binding at CHR promoter elements. Cell Cycle 11:4661–4672.  https://doi.org/10.4161/cc.22917 CrossRefGoogle Scholar
  50. Rosario CO et al (2010) Plk4 is required for cytokinesis and maintenance of chromosomal stability. Proc Natl Acad Sci USA 107:6888–6893.  https://doi.org/10.1073/pnas.0910941107 CrossRefGoogle Scholar
  51. Rosario CO et al (2015) A novel role for Plk4 in regulating cell spreading and motility. Oncogene 34:3441–3451.  https://doi.org/10.1038/onc.2014.275 CrossRefGoogle Scholar
  52. Rudolph D et al (2009) BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity. Clin Cancer Res 15:3094–3102.  https://doi.org/10.1158/1078-0432.ccr-08-2445 CrossRefGoogle Scholar
  53. Scharow A, Knappe D, Reindl W, Hoffmann R, Berg T (2016) Development of bifunctional inhibitors of polo-like kinase 1 with low-nanomolar activities against the polo-box domain. Chembiochem 17:759–767.  https://doi.org/10.1002/cbic.201500535 CrossRefGoogle Scholar
  54. Sercin O et al (2016) Transient PLK4 overexpression accelerates tumorigenesis in p53-deficient epidermis. Nat Cell Biol 18:100–110.  https://doi.org/10.1038/ncb3270 CrossRefGoogle Scholar
  55. Shinmura K, Kurabe N, Goto M, Yamada H, Natsume H, Konno H, Sugimura H (2014) PLK4 overexpression and its effect on centrosome regulation and chromosome stability in human gastric cancer. Mol Biol Rep 41:6635–6644.  https://doi.org/10.1007/s11033-014-3546-2 CrossRefGoogle Scholar
  56. Slevin LK, Nye J, Pinkerton DC, Buster DW, Rogers GC, Slep KC (2012) The structure of the plk4 cryptic polo box reveals two tandem polo boxes required for centriole duplication. Structure 20:1905–1917.  https://doi.org/10.1016/j.str.2012.08.025 CrossRefGoogle Scholar
  57. Spaniol K, Boos J, Lanvers-Kaminsky C (2011) An in vitro evaluation of the polo-like kinase inhibitor GW843682X against paediatric malignancies. Anti-cancer Drugs 22:531–542.  https://doi.org/10.1097/cad.0b013e3283454526 CrossRefGoogle Scholar
  58. Sredni ST et al (2017a) Inhibition of polo-like kinase 4 (PLK4): a new therapeutic option for rhabdoid tumors and pediatric medulloblastoma. Oncotarget 8:111190–111212.  https://doi.org/10.18632/oncotarget.22704 CrossRefGoogle Scholar
  59. Sredni ST et al (2017b) A functional screening of the kinome identifies the polo-like kinase 4 as a potential therapeutic target for malignant rhabdoid tumors, and possibly, other embryonal tumors of the brain. Pediatr Blood Cancer.  https://doi.org/10.1002/pbc.26551 Google Scholar
  60. Steegmaier M et al (2007) BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr Biol 17:316–322.  https://doi.org/10.1016/j.cub.2006.12.037 CrossRefGoogle Scholar
  61. Suri A et al (2019) Evaluation of protein kinase inhibitors with PLK4 cross-over potential in a pre-clinical model of cancer. Int J Mol Sci.  https://doi.org/10.3390/ijms20092112 Google Scholar
  62. Tian X et al (2018) Polo-like kinase 4 mediates epithelial-mesenchymal transition in neuroblastoma via PI3 K/Akt signaling pathway. Cell Death Dis 9:54.  https://doi.org/10.1038/s41419-017-0088-2 CrossRefGoogle Scholar
  63. Tsou MF, Stearns T (2006) Mechanism limiting centrosome duplication to once per cell cycle. Nature 442:947–951.  https://doi.org/10.1038/nature04985 CrossRefGoogle Scholar
  64. Valsasina B et al (2012) NMS-P937, an orally available, specific small-molecule polo-like kinase 1 inhibitor with antitumor activity in solid and hematologic malignancies. Mol Cancer Ther 11:1006–1016.  https://doi.org/10.1158/1535-7163.mct-11-0765 CrossRefGoogle Scholar
  65. Ward A, Hudson JW (2014) p53-Dependent and cell specific epigenetic regulation of the polo-like kinases under oxidative stress. PLoS One 9:e87918.  https://doi.org/10.1371/journal.pone.0087918 CrossRefGoogle Scholar
  66. Ward A, Morettin A, Shum D, Hudson JW (2011) Aberrant methylation of Polo-like kinase CpG islands in Plk4 heterozygous mice. BMC Cancer 11:71.  https://doi.org/10.1186/1471-2407-11-71 CrossRefGoogle Scholar
  67. Ward A, Sivakumar G, Kanjeekal S, Hamm C, Labute BC, Shum D, Hudson JW (2015) The deregulated promoter methylation of the Polo-like kinases as a potential biomarker in hematological malignancies. Leuk Lymphoma 56:2123–2133.  https://doi.org/10.3109/10428194.2014.971407 CrossRefGoogle Scholar
  68. Wong YL et al (2015) Reversible centriole depletion with an inhibitor of Polo-like kinase 4. Science 348:1155–1160.  https://doi.org/10.1126/science.aaa5111 CrossRefGoogle Scholar
  69. Wu J, Akhmanova A (2017) Microtubule-Organizing Centers. Annu Rev Cell Dev Biol 33:51–75.  https://doi.org/10.1146/annurev-cellbio-100616-060615 CrossRefGoogle Scholar
  70. Wu HY, Nazockdast E, Shelley MJ, Needleman DJ (2017) Forces positioning the mitotic spindle: Theories, and now experiments. BioEssays.  https://doi.org/10.1002/bies.201600212 Google Scholar
  71. Zhang Z et al (2019) PLK4 is a determinant of temozolomide sensitivity through phosphorylation of IKBKE in glioblastoma. Cancer Lett 443:91–107.  https://doi.org/10.1016/j.canlet.2018.11.034 CrossRefGoogle Scholar
  72. Zitouni S, Nabais C, Jana SC, Guerrero A, Bettencourt-Dias M (2014) Polo-like kinases: structural variations lead to multiple functions. Nat Rev Mol Cell Biol 15:433–452.  https://doi.org/10.1038/nrm3819 CrossRefGoogle Scholar
  73. Zitouni S et al (2016) CDK1 prevents unscheduled PLK4-STIL complex assembly in centriole biogenesis. Curr Biol 26:1127–1137.  https://doi.org/10.1016/j.cub.2016.03.055 CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of HematologyShandong Provincial Hospital Affiliated to Shandong UniversityJinanPeople’s Republic of China
  2. 2.School of MedicineShandong UniversityJinanChina
  3. 3.Shandong Provincial Engineering Research Center of LymphomaJinanChina
  4. 4.Key Laboratory for Kidney Regeneration of Shandong ProvinceJinanChina

Personalised recommendations